Objective: To investigate the differences in bone turnover between diabetic patients and controls. Design: A systematic review and meta-analysis. Methods: A literature search was conducted using the databases Medline at PubMed and EMBASE. The free text search terms 'diabetes mellitus' and 'bone turnover', 'sclerostin', 'RANKL', 'osteoprotegerin', 'tartrate-resistant acid' and 'TRAP' were used. Studies were eligible if they investigated bone turnover markers in patients with diabetes compared with controls. Data were extracted by two reviewers. Results: A total of 2881 papers were identified of which 66 studies were included. Serum levels of the bone resorption marker C-terminal cross-linked telopeptide (−0.10 ng/mL (−0.12, −0.08)) and the bone formation markers osteocalcin (−2.51 ng/mL (−3.01, −2.01)) and procollagen type 1 amino terminal propeptide (−10.80 ng/mL (−12.83, −8.77)) were all lower in patients with diabetes compared with controls. Furthermore, s-tartrate-resistant acid phosphatase was decreased in patients with type 2 diabetes (−0.31 U/L (−0.56, −0.05)) compared with controls. S-sclerostin was significantly higher in patients with type 2 diabetes (14.92 pmol/L (3.12, 26.72)) and patients with type 1 diabetes (3.24 pmol/L (1.52, 4.96)) compared with controls. Also, s-osteoprotegerin was increased among patients with diabetes compared with controls (2.67 pmol/L (0.21, 5.14)). Conclusions: Markers of both bone formation and bone resorption are decreased in patients with diabetes. This suggests that diabetes mellitus is a state of low bone turnover, which in turn may lead to more fragile bone. Altered levels of sclerostin and osteoprotegerin may be responsible for this.
Introduction
Patients with diabetes suffer from a higher risk of fracture than their healthy peers (1, 2) .
One way of assessing fracture risk is by estimating the bone mineral density (BMD) by dual X-ray absorptiometry (DXA) (3) . Interestingly, for patients with type 1 and type 2 diabetes, BMD underestimates the fracture risk. Compared with controls, patients with type 1 diabetes have a lower BMD and type 2 diabetes have a higher BMD, but these differences in BMD do not explain the observed increased fracture risk (4) . Bone tissue biopsies using histomorphometric analysis with dynamic indices may also evaluate bone turnover, but at present, clinical studies investigating bone tissue biopsies in patients with diabetes have been scarce and with no comparison between patients with type 1 and type 2 diabetes (5, 6, 7) . Bone turnover may be assessed by measuring biochemical markers. These bone markers reflect the bone turnover process and hence mirror the bone resorption and formation processes (8) and are known to be predictors of fracture in non-diabetes individuals (9) . Figure 1 depicts the process, regulators and products of bone turnover.
Numerous previous studies indicate that bone turnover markers differ in patients with diabetes and healthy controls (10, 11) , thus suggesting an altered bone metabolism in diabetic bone. A meta-analysis performed in 2014 revealed that osteocalcin and C-terminal crosslinked telopeptide (CTX) were significantly lower in patients with diabetes compared with controls, indicating a suppressed bone formation and resorption respectively (11). Since these findings were made, more studies have evaluated bone turnover markers in diabetes, including the bone marker sclerostin.
The role of sclerostin in diabetic bone turnover is controversial. Thus, it was recently proven that sclerostin levels are surprisingly inversely associated with fracture risk in patients with type 1 diabetes (12) , whereas increasing sclerostin levels have been associated with increased fracture risk in patients with type 2 diabetes (13, 14, 15) . The significance of this finding, however, so far defies solution.
The aim of the present study was to conduct an updated meta-analysis of the literature investigating the levels of biochemical markers of bone turnover in patients with diabetes types 1 and 2 compared with controls. The present study will also provide an overview of the current knowledge on the altered bone turnover in patients with diabetes.
Methods
The PRISMA guidelines (16) were used.
Data sources, searches and eligibility criteria
A systematic literature search was conducted in association with a research librarian in November 2015 and updated in September 2016. The databases Medline at PubMed and EMBASE (1974 EMBASE ( -2016 were explored using the free text search terms: 'diabetes mellitus' and 'bone turnover'. To avoid omitting studies investigating more seldom studied markers such as osteoprotegerin (OPG), receptor activator of nuclear factor kappa-B ligand (RANKL), sclerostin and tartrate-resistant acid phosphatase (TRAP), free text searches were performed using the terms: 'diabetes mellitus', 'sclerostin', 'RANKL', 'osteoprotegerin', 'tartrate-resistant acid', and 'TRAP'.
No restriction was applied regarding publication date. We chose to use free text terms to gather as many eligible studies as possible; however, the free text terms also lead to a number of irrelevant papers.
The eligibility criterion for the included studies was to investigate biochemical bone turnover markers in both patients with diabetes mellitus and in non-diabetic controls. Both observational and interventional studies were included. Different studies exploring identical populations were excluded, and only the study deemed of best quality by the authors were included. We investigated markers of bone resorption (CTX, N-terminal crosslinked telopeptide of type 1 collagen (NTX), and TRAP), bone formation (procollagen type 1 amino terminal propeptide (P1NP)), osteocalcin, and bone-specific alkaline phosphatase (BAP) and markers of bone turnover signaling (OPG, RANKL and sclerostin). Only the previously mentioned markers were eligible for our study. These specific markers were chosen to investigate whether bone turnover differs in patients with diabetes types 1 and 2 and in non-diabetic controls, and also to determine whether a bone signaling pathway may be affected.
Data extraction and quality assessment
The literature search recovered 1989 papers from EMBASE and 892 papers from Medline at PubMed after removing duplicates. Each full text paper was assessed by title and abstract, and if it was a possible candidate for inclusion in the meta-analysis, it was later assessed by full text to determine its eligibility. In total, 66 studies were included. The relevant data were extracted from each included paper and tabulated independently by J S-L and K H.
The data were screened by two authors (J S-L and K H). The data extracted from the papers included certain characteristics of the study population (age, BMI, gender, diabetes type and diabetes duration), study design, fasting status at the time of laboratory samples, follow-up years, glycated hemoglobin A1c (HbA1c), p-glucose at the time of measurement, markers of bone resorption and formation and bone turnover signaling markers. A single study may report several different populations available for analysis as they may present bone markers stratified by for example age or gender.
Data that may confound the observed bone turnover marker levels either due to clinical (age and gender) or methodological (design) impact were extracted from the relevant papers. A few studies classified diabetes as insulindependent diabetes mellitus (IDDM) or non-insulindependent diabetes mellitus (NIDDM). In the pooled analysis, these classifications have been converted to type 1 diabetes and type 2 diabetes respectively. NIDDM may only comprise patients with type 2 diabetes as patients with type 1 diabetes per definition are insulin dependent. The IDDM classification may hence contain both type 1 diabetes and type 2 diabetes patients, which may influence the results. Quality of studies was evaluated by two reviewers (J S-L and K H), and quality was ascertained by the modified Newcastle-Ottawa Scale adapted for crosssectional studies (17), Supplementary Fig. 1 (see section on supplementary data given at the end of this article). Studies of longitudinal and randomized controlled designs were quality assessed by the same scale.
Statistical analysis
The mean values and standard deviation or 95% confidence intervals of biochemical markers were evaluated. The common weighted mean difference (MD) and the standardized mean difference (SMD) were analyzed using the random effects model. The SMD takes assay and inter-laboratory differences into account as percentages are calculated. If no discrepancies were found when applying either the MD or the SMD, only the MD has been reported. For bone-specific alkaline phosphatase, only the standardized mean difference was estimated owing to concentrations being provided in both µmol/L and U/L for which no conversion factor is known. Pooled analyses were implemented if at least three populations were available. Heterogeneity among studies was determined by I 2 analysis. The possibility of a publication bias was evaluated visually by funnel plot. Subgroup analysis by type 1 diabetes and type 2 diabetes was performed. The RevMan 5.3 software program was applied. Meta-regression analysis was performed to assess the effect modification of plasma glucose values, HbA1c and diabetes duration using the difference in marker values between subjects with and without diabetes. Metaregression was performed separately for patients with type 1 and type 2 diabetes. To perform a meta-regression, data from at least three populations had to be available.
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Results

Search results
A total of 2881 papers were identified of which 66 studies were suitable for inclusion in the meta-analysis, Fig. 2 for study flow. The included studies comprised 62 crosssectional studies, three randomized controlled trials and one longitudinal study and differed in number of participants ranging from 16 to 890 patients with diabetes and from ten to 2053 non-diabetic controls. In general, the studies reported fasting bone turnover marker values and excluded patients with renal disease. The investigated populations ranged from children to the elderly. The quality of the studies was fair with a study quality score ranging between three and ten, and only two studies scored a study quality less than five. Table 1 shows the included studies regarding characteristics of participants, study size, levels of HbA1c and p-glucose, NewcastleOttawa Scale score and features of measurements of bone turnover markers. The total number of studies exploring the different bone turnover markers varied greatly from only seven studies reporting on levels of RANKL to 45 studies with data on osteocalcin.
Results for each meta-analysis
The resorptive bone turnover marker CTX was lower in patients with diabetes compared with controls (−0.10 ng/mL (−0.12, −0.08)). Figure 3 (0.21, 5.14), Supplementary Fig. 2 ). When analyzing the SMD, the result remained in favor of a higher level of OPG in diabetes compared with controls, however, insignificant (0.83 (−0.17, 1.83)). Sclerostin was borderline significantly higher for patients with diabetes compared with controls (10.51 pmol/L (−0.80, 21.81), Supplementary Fig. 3 ), the result was consistent when analyzing the SMD. No differences were observed between patients with diabetes and controls regarding the markers TRAP, NTX, BAP and RANKL, Supplementary Fig. 4 . All markers displayed significant heterogeneity with 65% heterogeneity being the lowest. Funnel plots evaluated visually were found adequate for all analyses with no publication bias.
Subgroup analysis by diabetes type
TRAP was significantly lower in patients with type 2 diabetes compared with controls (−0.31 U/L (−0.56, −0.05)), whereas no significance was apparent when comparing type 1 diabetes and controls (P = 0.90), Supplementary Fig. 5 .
Sclerostin was significantly higher in patients with type 2 diabetes compared with controls (14.92 pmol/L (3.12, 26.72)), which was also the case for patients with type 1 diabetes compared with controls (3.24 pmol/L (1.52, 4.96)). Figure 6 presents the pooled results of sclerostin for patients with type 1 and type 2 diabetes. In consistency with results on all patients with diabetes compared with controls, CTX was significantly lower in both type 1 (−0.10 (−0.18, −0.01)) and type 2 (−0.11 (−0.14, −0.09)) diabetes compared with controls, and osteocalcin was lower in both type 1 (−3.08 (−4.32, −1.83)) and type 2 (−2.63 (−3.24, −2.02)) diabetes compared with controls, Supplementary Figs 6 and 7 . P1NP was significantly lower in type 2 diabetes compared with controls (−10.45 (−12.53, −8.37)), but no significant difference was found regarding type 1 diabetes (P = 0.28), Supplementary Fig. 8 . For the remaining bone turnover markers, NTX, BAP, OPG and RANKL, no significant changes were observed when applying subgroup analyses, Supplementary Fig. 9 .
For all subgroup analyses, analyzing the SMD neither changes the results nor the significance of the results, apart from sclerostin in type 1 diabetes that remained higher compared with controls, however, insignificant (0.22 (−0.16, 0.60)).
Meta-regression
When comparing the difference in bone turnover marker levels between patients with type 1 diabetes and controls, the plasma glucose level was a significant effect modificator of osteocalcin (β = −3.97) and RANKL (β = 124), whereas HbA1c was a significant effect modificator of sclerostin (β = −0.08), Supplementary Table 1 . When comparing the differences in bone turnover marker levels between patients with type 2 diabetes and controls, the plasma glucose level was a significant effect modificator of NTX (β = −36.7) and osteoprotegerin (β = 3.47), whereas HbA1c was a significant effect modificator of P1NP (β = −1.10), osteocalcin (β = 1.28) and sclerostin (β = 9.23), 
Supplementary
Discussion
The results of the meta-analysis reported a decreased level of circulating bone turnover markers in patients with diabetes compared with non-diabetic controls concerning a variety of different bone resorption and formation markers. Increased levels of sclerostin and OPG may be responsible for this. CTX and P1NP have been suggested by the International Osteoporosis Foundation as the appropriate bone markers when exploring bone resorption and formation in clinical and research settings (18). Levels of CTX and osteocalcin were consistently lower in diabetes Figure 4 Pooled analysis of procollagen type 1 amino terminal propeptide (P1NP) levels in patients with diabetes compared with controls.
Studies with several populations comparing patients with diabetes and controls are explained as the author name followed by a, b, c or d to indicate for example subdivision by age, gender or BMI.
Study or Subgroup
Abdalrahman 2015 
Total (95% CI)
Heterogeneity: Tau² = 1.92; Chi² = 11866.52, df = 53 (P < 0.00001); I² = 100%
Test for overall effect: Z = 9.93 (P < 0.00001) compared with controls, regardless of diabetes type, indicating that both bone resorption and formation are lower in both types of diabetes compared with controls. P1NP, a formation marker, was also consistently lower in diabetes compared with controls, but insignificant in patients with type 1 diabetes compared with controls. This difference in P1NP may partly be due to the fact that only two studies are included exploring P1NP in patients with type 1 diabetes, whereas 20 studies are included regarding P1NP in patients with type 2 diabetes. Sclerostin was increased in both patients with type 1 and type 2 diabetes; however, the levels were more than four times higher in patients with type 2 diabetes compared with controls than in patients with type 1 diabetes compared with controls. For TRAP, RANKL, OPG, NTX and BAP, all estimates were insignificant for both diabetes as a whole and for each diabetes type except for TRAP, which was significantly lower in patients with type 2 diabetes compared with controls and OPG, which was significantly higher in diabetes as a whole compared with controls. Taken together, these results suggest that both type 1 and type 2 diabetes are states of low bone turnover. Patients with type 1 diabetes are insulinopenic though insulin sensitive and receive insulin treatment throughout life, whereas patients with type 2 diabetes often have varying levels of insulin but are insulin resistant. Furthermore, patients with type 2 diabetes are likely to have a higher BMI than compared with patients with type 1 diabetes.
Patients with type 2 diabetes tend to have higher BMD possibly due to a higher BMI, but on the other hand, hyperglycemia and insulin resistance may tend to suppress bone turnover. A recent cross-sectional study examining more than 3000 men found that in men with the metabolic syndrome, bone formation and resorption, as judged by CTX, P1NP and osteocalcin, were lower than compared with men without the metabolic syndrome. The association between the metabolic syndrome and bone turnover markers was particularly correlated with insulin sensitivity, indicating that insulin-resistant individuals may have lower bone turnover than their healthy peers (19) .
The decreased bone turnover in patients with diabetes may be explained by increased levels of sclerostin. Sclerostin levels were elevated in both patients with type 1 and type 2 diabetes compared with controls. Sclerostin levels were borderline significant when pooling patients with type 1 and type 2 diabetes probably due to wide Figure 6 Pooled analysis of sclerostin levels in patients with type 1 diabetes compared with controls at the top and pooled analysis of sclerostin levels in patients with type 2 diabetes compared with controls at the bottom.
confidence intervals resulting from the pooling of results. Sclerostin is released from the osteocytes and decreases osteoblast activity and indirectly also decreases osteoclast activity by inhibiting the secretion of OPG (20) .
In vitro studies report that hyperglycemia increases OPG expression in osteoblastic cell lines (21, 22) and increases sclerostin expression by osteocyte cell lines (23). Increasing plasma glucose levels is associated with increasing levels of OPG in patients with diabetes (24). Furthermore, serum levels of OPG decrease in non-diabetic women during an oral glucose tolerance test, whereas it is unaffected in women with type 2 diabetes (25). The lack of OPG response to oral glucose in women with type 2 diabetes may be caused by somewhat chronic hyperglycemia, which limits further reductions in OPG. Although current evidence is limited, both OPG and sclerostin may be increased in diabetes due to hyperglycemia. These increased levels of OPG and sclerostin may hence decrease bone turnover in patients with diabetes.
The results of the meta-regression suggest that hyperglycemia is a significant contributor to the differences in osteocalcin, RANKL and sclerostin in patients with type 1 diabetes compared with controls and a significant contributor to the differences in P1NP, osteocalcin, NTX, osteoprotegerin, RANKL and sclerostin in patients with type 2 diabetes compared with controls. A methodological study has previously reported that hyperglycemia does not interfere with the measurement of CTX, P1NP and osteocalcin (11); thus, the observed association in this meta-analysis and meta-regression is unlikely to stem from measurement error. In vitro, hyperglycemia decreases osteoclast and osteoblast function and may thus lead to decreased bone turnover (26, 27). In patients with diabetes, increasing plasma glucose is associated with decreased levels of CTX, P1NP and osteocalcin (24). An oral glucose tolerance test decreases bone turnover markers in healthy individuals, but the effect is abolished by somatostatin (28), suggesting that hyperglycemia in combination with a gastro-intestinal hormone response may decrease bone turnover.
Incretins including gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) have been suggested as being partly responsible for the altered bone turnover in diabetes. Physiologically, incretins are secreted postprandially and lower blood glucose by enhancing the insulin response. Incretins are known suppressors of bone resorption, and it has previously been shown in vitro and in animal studies that GLP-1 reduces bone resorption (29, 30, 31) . A recent clinical trial concluded that treatment with a GLP-1 analogue increases bone formation possibly by decreasing bone resorption in obese women (32) . Patients with type 1 diabetes have normal postprandial levels of both GIP and GLP-1 (33) , and traditionally, patients with type 2 diabetes are thought to have low levels of incretins, which would contribute to an impaired insulin response to hyperglycemia. Surprisingly, studies on plasma levels of GLP-1 in patients with type 2 diabetes report conflicting results with both reduced (34, 35) and non-reduced (36, 37) levels. Further clinical studies are warranted to establish the effect of incretins on bone turnover in diabetic individuals, especially in patients with type 2 diabetes.
Insulin-like growth factor-1 (IGF-1) recruits additional osteoblasts during bone formation and may be of importance when explaining the low bone turnover marker levels in patients with diabetes (38) . Furthermore, decreased levels of IGF-1 have been associated with fractures in patients with diabetes and may be a potential fracture predictor (15) . However, further research is needed to determine the effect of IGF on bone turnover and fracture risk.
Although bone tissue biopsies are the gold standard when estimating bone turnover, biopsies are difficult to obtain. Two human studies found low bone turnover in diabetes compared with controls evaluated by bone tissue biopsies (5, 6) . Bone biopsies were performed in eight and five patients with diabetes respectively (5, 6). Another study in 18 patients with type 1 diabetes did not show any differences in bone turnover compared to non-diabetes subjects (7) . These patients were well controlled with a mean HbA1c of 6.8% (7), which may influence the results as the fracture risk is highest in patients with HbA1c levels above 9% (39) .
A decreased bone turnover may increase bone fragility in patients with diabetes. Diabetic bone is suggested to be more fragile due to glycation of the collagen, which decreases cross-link strength (40). BAP, a marker of mineralization, was in the present study not decreased in patients with diabetes compared with controls. We propose that the bone turnover process may in itself be uncoupled with a decreased bone resorption and formation but an intact mineralization. Thus, BMD may be increased by this mechanism in patients with diabetes. Although the meta-analysis does not evaluate fracture prediction by bone turnover markers, decreased levels of osteocalcin (41) and increased levels of sclerostin (13, 15) were previously associated with prevalent fractures in patients with diabetes. Larger cohort studies are needed to determine the predictive value of bone turnover markers in patients with diabetes and the consequences thereof.
The strength of the meta-analysis is that a high number of studies are included and the results are thus likely to be generalizable to the entire population of patients with diabetes. Furthermore, we have been able to evaluate different bone turnover markers. Both the MD and SMD tests have been performed to limit confounding by inter-laboratory differences.
A limitation to the study is that the included data are based mainly on observational studies. No information on use of antidiabetic drugs or comorbidities was collected. The effects of antidiabetic drugs on bone and bone turnover differ greatly. Metformin has been shown in clinical and observational studies to execute a neutral or beneficial effect on bone regarding fracture risk, as has also been proposed for the incretins such as DPP4 inhibitors and GLP-1 analogues. The thiazolidinediones rosiglitazone and pioglitazone have a harmful effect on bone including an increased fracture risk, possibly due to increased bone loss. Sulfonylureas affect bone in a neutral way. SGLT2-inhibitors may have a neutral or possibly harmful effect on fracture risk. Insulin may have a favorable effect on bone with a lower risk of fracture, but clinical data are scarce and the effect may be secondary to a positive effect on blood glucose and diabetes as a whole (42, 43) . As antidiabetic drugs may influence bone turnover and fracture risk in a variety of ways, it is unlikely to explain the observed results owing to the large number of heterogeneous studies included.
Studies of patients with different PTH and vitamin D levels have been included in the meta-analysis, which may affect the results.
Renal function is known to affect bone turnover and bone turnover markers (44) . Renal dysfunction was a general exclusion criteria in most studies, and if not, both the diabetes and the control group had similar renal dysfunction, deeming kidney function unlikely to affect the study and the estimated effect.
The fasting status may affect especially CTX (45) and although not all samples were collected in a fasting state, similar circumstances were applied for patients with diabetes and for controls.
In conclusion, bone turnover markers were decreased in patients with diabetes compared with controls. Elevated sclerostin and OPG levels may be responsible for this. The decrease in bone turnover markers may be due to hyperglycemia and an altered incretin response. Clinically, the decreased bone turnover may be a contributor to increased bone fragility in patients with diabetes.
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